Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 7/2005

01.07.2005 | Article

Imported leishmaniasis in Germany 2001–2004: data of the SIMPID surveillance network

verfasst von: T. Weitzel, N. Mühlberger, T. Jelinek, M. Schunk, S. Ehrhardt, C. Bogdan, K. Arasteh, T. Schneider, W. V. Kern, G. Fätkenheuer, G. Boecken, T. Zoller, M. Probst, M. Peters, T. Weinke, S. Gfrörer, H. Klinker, M.-L. Holthoff-Stich, Surveillance Importierter Infektionen in Deutschland (SIMPID) Surveillance Network

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 7/2005

Einloggen, um Zugang zu erhalten

Abstract

Leishmaniasis is a rare, non-notifiable disease in Germany. Epidemiological and clinical data, therefore, are scarce. Most infections seen in Germany are contracted outside the country. The German surveillance network for imported infectious diseases (Surveillance Importierter Infektionen in Deutschland, or SIPMID) recorded 42 cases of imported leishmaniasis (16 visceral, 23 cutaneous, and 3 mucocutaneous) from January 2001 to June 2004. Although most infections were acquired in European Mediterranean countries, the risk of infection was highest for travelers to Latin America. HIV coinfection was observed significantly more often in patients with visceral leishmaniasis than in patients with cutaneous/mucocutaneous leishmaniasis (31 vs. 4%, p=0.02). The median time to a definitive diagnosis was 85 days in cases of visceral leishmaniasis and 61 days in cases of cutaneous/mucocutaneous leishmaniasis, reflecting the unfamiliarity of German physicians with leishmanial infections. Visceral leishmaniasis was treated most frequently with amphotericin B, whereas cutaneous/mucocutaneous leishmaniasis was treated with a variety of local and systemic therapies. The findings presented here should serve to increase awareness as well as improve clinical management of leishmaniasis in Germany.
Literatur
1.
2.
Zurück zum Zitat Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27:305–318PubMed Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27:305–318PubMed
3.
Zurück zum Zitat Rose K, Curtis J, Baldwin T, Mathis A, Kumar B, Sakthianandeswaren A, Spurck T, Low Choy J, Handman E (2004) Cutaneous leishmaniasis in red kangaroos: isolation and characterisation of the causative organisms. Int J Parasitol 34:655–664PubMed Rose K, Curtis J, Baldwin T, Mathis A, Kumar B, Sakthianandeswaren A, Spurck T, Low Choy J, Handman E (2004) Cutaneous leishmaniasis in red kangaroos: isolation and characterisation of the causative organisms. Int J Parasitol 34:655–664PubMed
4.
Zurück zum Zitat Ashford RW (1996) Leishmaniasis reservoirs and their significance in control. Clin Dermatol 14:523–532PubMed Ashford RW (1996) Leishmaniasis reservoirs and their significance in control. Clin Dermatol 14:523–532PubMed
5.
Zurück zum Zitat Seaman J, Mercer AJ, Sondorp HE, Herwaldt BL (1996) Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med 124:664–672PubMed Seaman J, Mercer AJ, Sondorp HE, Herwaldt BL (1996) Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med 124:664–672PubMed
6.
Zurück zum Zitat Hewitt S, Reyburn H, Ashford R, Rowland M (1998) Anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: vertical distribution of cases in apartment blocks. Trans R Soc Trop Med Hyg 92:273–274PubMed Hewitt S, Reyburn H, Ashford R, Rowland M (1998) Anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: vertical distribution of cases in apartment blocks. Trans R Soc Trop Med Hyg 92:273–274PubMed
7.
Zurück zum Zitat Magill AJ, Grogl M, Gasser RA Jr, Sun W, Oster CN (1993) Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 328:1383–1387PubMed Magill AJ, Grogl M, Gasser RA Jr, Sun W, Oster CN (1993) Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 328:1383–1387PubMed
8.
Zurück zum Zitat Alvar J, Canavate C, Gutierrez-Solar B, Jimenez M, Laguna F, Lopez-Velez R, Molina R, Moreno J (1997) Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 10:298–319PubMed Alvar J, Canavate C, Gutierrez-Solar B, Jimenez M, Laguna F, Lopez-Velez R, Molina R, Moreno J (1997) Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 10:298–319PubMed
9.
Zurück zum Zitat Anonymous (2002) Reiseassoziierte Infektionskrankheiten in Deutschland 2001 Epidemiologisches Bulletin: 285–296 Anonymous (2002) Reiseassoziierte Infektionskrankheiten in Deutschland 2001 Epidemiologisches Bulletin: 285–296
11.
Zurück zum Zitat Statistisches Bundesamt (2004) Tourismus in Zahlen 2003. Statistisches Bundesamt, Wiesbaden, Germany Statistisches Bundesamt (2004) Tourismus in Zahlen 2003. Statistisches Bundesamt, Wiesbaden, Germany
12.
Zurück zum Zitat Harms G, Schonian G, Feldmeier H (2003) Leishmaniasis in Germany. Emerg Infect Dis 9:872–875PubMed Harms G, Schonian G, Feldmeier H (2003) Leishmaniasis in Germany. Emerg Infect Dis 9:872–875PubMed
13.
Zurück zum Zitat Bravo F, Sanchez MR (2003) New and re-emerging cutaneous infectious diseases in Latin America and other geographic areas. Dermatol Clin 21:655–668PubMed Bravo F, Sanchez MR (2003) New and re-emerging cutaneous infectious diseases in Latin America and other geographic areas. Dermatol Clin 21:655–668PubMed
14.
Zurück zum Zitat Lawn SD, Whetham J, Chiodini PL, Kanagalingam J, Watson J, Behrens RH, Lockwood DN (2004) New World mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM 97:781–788PubMed Lawn SD, Whetham J, Chiodini PL, Kanagalingam J, Watson J, Behrens RH, Lockwood DN (2004) New World mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM 97:781–788PubMed
15.
Zurück zum Zitat Davies CR, Reithinger R, Campbell-Lendrum D, Feliciangeli D, Borges R, Rodriguez N (2000) The epidemiology and control of leishmaniasis in Andean countries. Cad Saude Publica 16:925–950PubMed Davies CR, Reithinger R, Campbell-Lendrum D, Feliciangeli D, Borges R, Rodriguez N (2000) The epidemiology and control of leishmaniasis in Andean countries. Cad Saude Publica 16:925–950PubMed
16.
Zurück zum Zitat Centers for disease control and prevention (2004) Update: cutaneous leishmaniasis in U.S. military personnel—Southwest/Central Asia, 2002–2004. MMWR Morb Mortal Wkly Rep 53:264–265 Centers for disease control and prevention (2004) Update: cutaneous leishmaniasis in U.S. military personnel—Southwest/Central Asia, 2002–2004. MMWR Morb Mortal Wkly Rep 53:264–265
17.
Zurück zum Zitat World Health Organisation (2002) Urbanization: an increasing risk factor for leishmaniasis. Wkly Epidemiol Rec 77:365–370 World Health Organisation (2002) Urbanization: an increasing risk factor for leishmaniasis. Wkly Epidemiol Rec 77:365–370
18.
Zurück zum Zitat El Hajj L, Thellier M, Carriere J, Bricaire F, Danis M, Caumes E (2004) Localized cutaneous leishmaniasis imported into Paris: a review of 39 cases. Int J Dermatol 43:120–125PubMed El Hajj L, Thellier M, Carriere J, Bricaire F, Danis M, Caumes E (2004) Localized cutaneous leishmaniasis imported into Paris: a review of 39 cases. Int J Dermatol 43:120–125PubMed
19.
Zurück zum Zitat Herwaldt BL, Stokes SL, Juranek DD (1993) American cutaneous leishmaniasis in U.S. travelers. Ann Intern Med 118:779–784PubMed Herwaldt BL, Stokes SL, Juranek DD (1993) American cutaneous leishmaniasis in U.S. travelers. Ann Intern Med 118:779–784PubMed
20.
Zurück zum Zitat Alexander J (1988) Sex differences and cross-immunity in DBA/2 mice infected with L. mexicana and L. major. Parasitology 96(Pt 2):297–302PubMed Alexander J (1988) Sex differences and cross-immunity in DBA/2 mice infected with L. mexicana and L. major. Parasitology 96(Pt 2):297–302PubMed
21.
Zurück zum Zitat Melby PC, Kreutzer RD, McMahon-Pratt D, Gam AA, Neva FA (1992) Cutaneous leishmaniasis: review of 59 cases seen at the National Institutes of Health. Clin Infect Dis 15:924–937PubMed Melby PC, Kreutzer RD, McMahon-Pratt D, Gam AA, Neva FA (1992) Cutaneous leishmaniasis: review of 59 cases seen at the National Institutes of Health. Clin Infect Dis 15:924–937PubMed
22.
Zurück zum Zitat Gradoni L, Bryceson A, Desjeux P (1995) Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 73:191–197PubMed Gradoni L, Bryceson A, Desjeux P (1995) Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 73:191–197PubMed
23.
Zurück zum Zitat Davies CR, Kaye P, Croft SL, Sundar S (2003) Leishmaniasis: new approaches to disease control. BMJ 326:377–382PubMed Davies CR, Kaye P, Croft SL, Sundar S (2003) Leishmaniasis: new approaches to disease control. BMJ 326:377–382PubMed
24.
Zurück zum Zitat Rosenthal E, Marty P (2003) Recent understanding in the treatment of visceral leishmaniasis. J Postgrad Med 49:61–68PubMed Rosenthal E, Marty P (2003) Recent understanding in the treatment of visceral leishmaniasis. J Postgrad Med 49:61–68PubMed
26.
Zurück zum Zitat Arana B, Rizzo N, Diaz A (2001) Chemotherapy of cutaneous leishmaniasis: a review. Med Microbiol Immunol (Berl) 190:93–95 Arana B, Rizzo N, Diaz A (2001) Chemotherapy of cutaneous leishmaniasis: a review. Med Microbiol Immunol (Berl) 190:93–95
27.
Zurück zum Zitat World Health Organisation (1984) The leishmaniases. Technical report series no. 701. WHO, Geneva, Switzerland World Health Organisation (1984) The leishmaniases. Technical report series no. 701. WHO, Geneva, Switzerland
28.
Zurück zum Zitat Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H (2004) Miltefosine for New World cutaneous leishmaniasis. Clin Infect Dis 38:1266–1272PubMed Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H (2004) Miltefosine for New World cutaneous leishmaniasis. Clin Infect Dis 38:1266–1272PubMed
Metadaten
Titel
Imported leishmaniasis in Germany 2001–2004: data of the SIMPID surveillance network
verfasst von
T. Weitzel
N. Mühlberger
T. Jelinek
M. Schunk
S. Ehrhardt
C. Bogdan
K. Arasteh
T. Schneider
W. V. Kern
G. Fätkenheuer
G. Boecken
T. Zoller
M. Probst
M. Peters
T. Weinke
S. Gfrörer
H. Klinker
M.-L. Holthoff-Stich
Surveillance Importierter Infektionen in Deutschland (SIMPID) Surveillance Network
Publikationsdatum
01.07.2005
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 7/2005
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-005-1363-1

Weitere Artikel der Ausgabe 7/2005

European Journal of Clinical Microbiology & Infectious Diseases 7/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.